Congress Scientific Watch

From ESMO Breast Cancer 2023:
Patients given neoadjuvant atezolizumab alongside chemotherapy for stage II–III triple-negative breast cancer are more likely to achieve pathological complete response but do not have better survival 

From ESMO Breast Cancer 2023:
Patients who do not achieve a complete response to neoadjuvant therapy for early-stage triple-negative breast cancer and have ctDNA after additional capecitabine are at high risk of recurrence 

From ESMO Breast Cancer 2023:
Patients with ER-low breast cancer may have disease with similar behaviours to those of their ER-negative counterparts

From ESMO Breast Cancer 2023:
Obesity is associated with poorer disease-free survival than normal weight after postmenopausal hormone receptor-positive breast cancer for women younger than 60 years, but may not affect older patients 

From ESMO Breast Cancer 2023:
The addition of capivasertib to fulvestrant improves progression-free survival for key subgroups of patients with hormone receptor-positive, HER2-negative advanced breast cancer resistant to aromatase inhibitors

From the 2023 AACR Annual Meeting:
RLY-2608, a mutant-selective PI3Kα inhibitor, may offer patients with PIK3CA-mutant solid tumours a chance of treatment without experiencing the toxic effects of non-selective PI3Kα inhibition  

From the 2023 AACR Annual Meeting:
Patients with gliomas, gynaecological tumours and pancreatic cancer could benefit from treatment with pemigatinib if they harbour an FGFR mutation

From the 2023 AACR Annual Meeting:
Some children and adolescents with solid tumours harbouring gene alterations may benefit from a combination of olaparib plus ceralasertib 

From the 2023 AACR Annual Meeting:
Preliminary results suggest REGN5459 has efficacy as a treatment for patients with heavily pretreated multiple myeloma

From the 2023 AACR Annual Meeting:
Patients with advanced desmoplastic melanoma have achieved a high objective response rate to pembrolizumab monotherapy

From ELCC 2023:
Post-hoc exploratory findings suggest that four cycles of chemotherapy followed by tremelimumab and durvalumab may optimise tumour shrinkage for metastatic non-small-cell lung cancer  

From ELCC 2023:
HLA-I expression in non-small-cell lung cancer may help predict response to immunotherapy